Novel strategies for the treatment of grass pollen-induced allergic rhinitis
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Introduction Allergic rhinitis (AR) affects over 20% of the population of Europe and the United States. Allergen immunotherapy (AIT) is currently the only form of treatment that affects symptoms and modifies the progression of disease. Established forms of AIT include subcutaneous (SCIT) and sublingual (SLIT) immunotherapy and are widely effective, yet only 2-9% of eligible patients undergo therapy, likely due to the long duration of treatment. As a result, novel, faster forms of AIT are currently under development. Areas covered This article provides an overview of AR and summarises the efficacy and mechanisms of established forms of AIT, highlighting the current drawbacks. We discuss novel strategies of AIT that have been developed in an attempt to tackle these limitations, including epicutaneous, intradermal and intralymphatic immunotherapy (ILIT), focusing on ILIT, the treatment that has been most comprehensively assessed. Expert opinion Current strategies to treat AR suffer from a poor safety profile and, importantly, lack of adherence. ILIT is a faster and safer form of AIT, with a treatment regime of only 12 weeks. Further validation is required, but ILIT, with its short and comparatively inexpensive protocol, has the potential to offer disease-modifying therapy to a larger number of patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The epidermis is rich in APCs while being less vascularized potentially reducing the risk for systemic reaction.1707,1708”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [1707]
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729 · cited 4×
“AR is currently subdivided into subtype (intermittent (IAR) or persistent (PER) disease) [7], as well as according to severity (mild and moderate/severe).”
BackgroundMethodInfluentialBeasley, R. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07302-9 · Cited by 3,389
The development of allergic inflammation
Galli, S. J., Tsai, M., & Piliponsky, A. M. (2008) · Nature · doi:10.1038/nature07204 · Cited by 1,839 · cited 13×
“AR is an IgE-mediated disease characterized by nasal obstruction, rhinorrhea, postnasal drip, nasal itching and sneezing [7].”
BackgroundInfluentialAllergen immunotherapy: A practice parameter third update
Cox, L., Nelson, H., Lockey, R., Calabria, C., Chacko, T., Finegold, I., Nelson, M., Weber, R., Bernstein, D. I., Blessing-Moore, J., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.09.034 · Cited by 1,256 · cited 1×
“patients receiving SCIT [36] and 75% of patients receiving SLIT [37], but tend to be mild and not deemed bothersome, with only 4% of SCIT patients considering discontinuation because of local reactions [38].”
BackgroundAkdis, M., Verhagen, J., Taylor, A., Karamloo, F., Karagiannidis, C., Crameri, R., Thunberg, S., Deniz, G., Valenta, R., Fiebig, H., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20032058 · Cited by 1,052
Prevalence and rate of diagnosis of allergic rhinitis in Europe
Bauchau, V., & Durham, S. R. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00013904 · Cited by 1,022 · cited 6×
“Direct costs (medical) of AR in the United States alone are estimated to be over $12 billion, with indirect costs (lost work productivity) being considerably greater [3].”
BackgroundInfluentialJacobsen, L., Niggemann, B., Dreborg, S., Ferdousi, H. A., Halken, S., Høst, A., Koivikko, A., Norberg, L. A., Valovirta, E., Wahn, U., et al. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01451.x · Cited by 976
Immune surveillance in the skin: mechanisms and clinical consequences
Kupper, T. S., & Fuhlbrigge, R. C. (2004) · Nature Reviews Immunology · doi:10.1038/nri1310 · Cited by 805
Allergen injection immunotherapy for seasonal allergic rhinitis
Calderon, M. A., Alves, B., Jacobson, M., Hurwitz, B., Sheikh, A., & Durham, S. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001936.pub2 · Cited by 678 · cited 2×
“demonstrated that immediate grade 3 or 4 (severe) adverse events following SCIT for seasonal AR were evident in 13 and 9 RCTs, respectively [23].”
Background
Research works printed but not linked: 2
- Calderon MA, 2007, Cochrane Database Syst Rev, 1, CD001936
- Mansson A, 2010, J Investig Allergol Clin Immunol, 20, 476
Cited by
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
Poaceae pollen as the leading aeroallergen worldwide: A review
García‐Mozo, H. (2017) · Allergy · doi:10.1111/all.13210 · Cited by 197
Molecular Aspects of Allergen-Specific Immunotherapy in Patients with Seasonal Allergic Rhinitis
Izmailovich, M. R., Semenova, Y. M., Abdushukurova, G., Mukhamejanova, A., А.А., Д., Faizova, R., Gazaliyeva, M., Akhvlediani, L., Glushkova, N., Kalmakhanov, S. B., et al. (2023) · Cells · doi:10.3390/cells12030383 · Cited by 36
Meteorological factors driving airborne grass pollen concentration in central Iberian Peninsula
Romero-Morte, J., Rojo, J., & Pérez-Badía, R. (2020) · Aerobiologia · doi:10.1007/s10453-020-09647-7 · Cited by 17
Jiang, S., Xie, S., Tang, Q., Zhang, H., Xie, Z., Zhang, J., & Jiang, W. (2023) · Mediators of Inflammation · doi:10.1155/2023/9377518 · Cited by 13
Metadata
- Authors
- Larsson, O., Hellkvist, L., Peterson-Westin, U., & Cardell, L. O.
- Affiliations
- Karolinska Institutet (SE)
- Karolinska University Hospital (SE)
- Corresponding author
- Cardell, Lars Olaf
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-06-09
- Volume
- 16
- Issue
- 9
- Pages
- 1143-1150
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2418754072
- Cited by
- 16
- References
- 70
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1
- FWCI
- 0.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- allergic rhinitis, grass pollen allergy, allergen immunotherapy, intralymphatic immunotherapy, epicutaneous immunotherapy, intradermal immunotherapy, sublingual immunotherapy, subcutaneous immunotherapy, medication adherence, immunotherapy safety, disease-modifying therapy
- MeSH terms
- Allergens, Animals, Desensitization, Immunologic, Europe, Poaceae, Humans, Injections, Intralymphatic, Pollen, Time Factors, United States, Treatment Outcome, Sublingual Immunotherapy, Rhinitis, Allergic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel strategies for the treatment of grass pollen-induced allergic rhinitis. https://app.cochat.ai/papers/10.1080/14712598.2016.1190829
- The paper
- Larsson, O., Hellkvist, L., Peterson-Westin, U., & Cardell, L. O. (2016). Novel strategies for the treatment of grass pollen-induced allergic rhinitis. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2016.1190829
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.